Mural Oncology PLC DEF 14A proxy statements

Mural Oncology plc reminds shareholders to vote on proposals for both the Scheme Meeting and Extraordinary General Meeting by October 23, 2025, concerning an acquisition.

Mural Oncology plc shareholders are set to vote on October 24, 2025, on the proposed acquisition by XRA 5 Corp, a subsidiary of XOMA Royalty Corporation, for a cash consideration of $2.035 to $2.24 per share.

Mural Oncology plc announces the publication of the Rule 15 Proposal and definitive proxy statement related to its acquisition by XOMA Royalty Corporation for cash.

Mural Oncology plc details the treatment of equity awards for its proposed acquisition by XRA 5 Corp., a subsidiary of XOMA Royalty Corporation, for a cash consideration of $2.035 to $2.24 per share.

Mural Oncology plc has commenced mailing its definitive proxy statement to shareholders regarding the acquisition by XOMA Royalty Corporation via a scheme of arrangement.

Mural Oncology plc shareholders to vote on a scheme of arrangement for acquisition by XOMA Royalty Corporation, offering $2.035 to $2.24 per share in cash.

Mural Oncology plc has entered into a definitive agreement to be acquired by XRA 5 Corp., a wholly-owned subsidiary of XOMA Royalty Corporation, for a cash consideration of $2.035 to $2.24 per share.

Mural Oncology plc will hold its Annual General Meeting on June 11, 2025, to elect directors and ratify the selection of PricewaterhouseCoopers LLP as the company's independent auditor.

Mural Oncology plc will hold its 2025 Annual General Meeting on June 11, 2025, to vote on the election of directors and the ratification of the independent auditor.

Mural Oncology plc will hold its Annual General Meeting on May 30, 2024, with shareholders voting on the election of directors and ratification of the company's independent auditor.

Mural Oncology plc has scheduled its 2024 Annual General Meeting (AGM) for May 30, 2024, to address director elections and auditor ratification.